# A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors

> **NCT04452955** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Intra-IMMUSG Pte Ltd** · enrollment: 51 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **BIOLOGICAL:** PRL3-zumab

## Key facts

- **NCT ID:** NCT04452955
- **Lead sponsor:** Intra-IMMUSG Pte Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-12-12
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2026-04-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04452955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04452955, "A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04452955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*